Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
93
93 articles ont été cités au moins 93fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
49 892
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
856
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
354
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre National de la Recherche Scientifique · Inserm · Institut Necker Enfants Malades
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Risk score for lower-limb amputation and its ability to predict major kidney and cardiovascular events in people with type 1 diabetes
2026ArticleCardiovascular Diabetology
Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes
2024ArticleDiabetes Care
Exploring the role of purinergic receptor P2RY1 in type 2 diabetes risk and pathophysiology: Insights from human functional genomics
2024ArticleMolecular metabolism
Functional genetics reveals the contribution of delta opioid receptor to type 2 diabetes and beta-cell function
2024ArticleNature Communications
Genetic predisposition to nephropathy and associated cardiovascular disease in people with type 1 diabetes: role of the angiotensinI-converting enzyme (ACE), and beyond; a narrative review.
2024ArticleCardiovascular Diabetology
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
2023ArticleNature Metabolism
The impact of race/ethnicity on the clinical outcomes of people with type 2 diabetes admitted to hospital with COVID-19: an observational multi-national analysis
2023ArticleBritish Journal of Diabetes
Genetic variants of interferon-response factor 5 are associated with the incidence of chronic kidney disease: the D.E.S.I.R. study
2023ArticleGenes and Immunity
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR MICHEL MARRE
CLINIQUE AMBROISE PARE 27 BOULEVARD VICTOR HUGO, 92200 NEUILLY SUR SEINE
CABINET DU DR MICHEL MARRE
HARTMANN GROUPEMENT HOSPITALIER AMBROISE PARE 48 TER BOULEVARD VICTOR HUGO, 92200 NEUILLY SUR SEINE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Diabetes care · 2021
OBJECTIVE To develop a frailty index (FI) and explore the relationship of frailty to subsequent adverse outcomes on the effectiveness and safety of more intensive control of both blood glucose and blood pressure (BP), among participants with type 2 diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. RESEARCH DESIGN AND METHODS Cox proportional hazard models were used to estimate the effectiveness and safety of intensive glucose control and BP intervention according to frailty (defined as FI >0.21) status. The primary outcomes were macro- and microvascular events. The secondary outcomes were all-cause mortality, cardiovascular mortality, severe hypoglycemia, and discontinuation of BP treatment due to hypotension/dizziness. RESULTS There were 11,140 participants (mean age, 65.8 years; 42.5% women, 25.7% frail). Frailty was an independent predictor of all primary outcomes and secondary outcomes. The effect of intensive glucose treatment on primary outcomes showed some evidence of attenuation in the frail: hazard ratios for combined major macro- and microvascular events 1.03 (95% CI 0.90–1.19) in the frail versus 0.84 (95% CI 0.74–0.94) in the nonfrail (P = 0.02). A similar trend was observed with BP intervention. Severe hypoglycemia rates (per 1,000 person-years) were higher in the frail: 8.39 (6.15–10.63) vs. 4.80 (3.84–5.76) in nonfrail (P < 0.001). There was no significant difference in discontinuation of BP treatment between frailty groups. CONCLUSIONS It was possible to retrospectively estimate frailty in a trial population, and this FI identified those at higher risk of poor outcomes. Participants with frailty had some attenuation of benefit from intensive glucose-lowering and BP-lowering treatments.
Diabetes, obesity & metabolism · 2022
Abstract Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO‐DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on the treatment effect of finerenone. Materials and Methods Patients with type 2 diabetes, urine albumin‐to‐creatinine ratio (UACR) 30‐5000 mg/g and estimated glomerular filtration rate 25‐<75 ml/min per 1.73 m 2 receiving optimized renin‐angiotensin system blockade were randomized to finerenone or placebo. Results Of the 5674 patients analysed, overall, 394 (6.9%) received GLP‐1RAs at baseline. A reduction in UACR with finerenone was observed with or without baseline GLP‐1RA use; ratio of least‐squares means 0.63 (95% confidence interval 0.56, 0.70) with GLP‐1RA use and 0.69 (95% confidence interval 0.67, 0.72) without GLP‐1RA use ( p value for interaction .20). Finerenone also significantly reduced the primary kidney (time to kidney failure, sustained decrease in estimated glomerular filtration rate ≥40% from baseline, or renal death) and key secondary CV outcomes (time to CV death, non‐fatal myocardial infarction, non‐fatal stroke, or hospitalization for heart failure) versus placebo, with no clear difference because of GLP‐1RA use at baseline ( p value for interaction .15 and .51 respectively) or any time during the trial. The safety profile of finerenone was similar between subgroups. Conclusions This exploratory subgroup analysis suggests that finerenone reduces UACR in patients with or without GLP‐1RA use at baseline, and the effects on kidney and CV outcomes are consistent irrespective of GLP‐1RA use.
The lancet. Diabetes & endocrinology · 2023
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Cardiovascular diabetology · 2025 · Journal Article
Af Geijerstam P, Chalmers J, Pikkemaat M, Peters R, et al.
BMJ open diabetes research & care · 2025 · Journal Article
Cahill LE, Warren RA, Lavallée SK, Levy AP, et al.
Diabetes care · 2025 · Journal Article
Ohkuma T, Harris K, Woodward M, Hamet P, et al.
Diabetes, obesity & metabolism · 2024 · Journal Article
Pikkemaat M, Woodward M, Af Geijerstam P, Harrap S, et al.
Journal of hypertension · 2024 · Journal Article
Wang N, Chalmers J, Harris K, Poulter N, et al.
Diabetes care · 2024 · Journal Article
Cahill LE, Warren RA, Carew AS, Levy AP, et al.
The lancet. Diabetes & endocrinology · 2023 · Journal Article
Folon L, Baron M, Toussaint B, Vaillant E, et al.
Cardiovascular diabetology · 2022 · Journal Article
Sanchez M, Kannengiesser C, Hoang S, Potier L, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021 · Journal Article
Fumeron F, El Boustany R, Bastard JP, Fellahi S, et al.
Diabetes, obesity & metabolism · 2021 · Journal Article
Jun M, Harris K, Heerspink HJL, Badve SV, et al.
Diabetes, obesity & metabolism · 2021 · Journal Article
Ohkuma T, Chalmers J, Cooper M, Hamet P, et al.
Diabetologia · 2021 · Journal Article
Bertrand C, Saulnier PJ, Potier L, Croyal M, et al.
Journal of diabetes · 2020 · Journal Article
Kim H, Wang D, Chalmers J, Jun M, et al.
Diabetes care · 2020 · Journal Article
Foussard N, Saulnier PJ, Potier L, Ragot S, et al.
Journal of the American Society of Nephrology : JASN · 2025 · Journal Article
Cole JB, Dahlström EH, Fermin D, Gupta Y, et al.
Genes and immunity · 2023 · Journal Article
Fumeron F, Velho G, Alzaid F, El Boustany R, et al.
Cells · 2022 · Journal Article
Mohammedi K, Marre M, Hadjadj S, Potier L, et al.
Diabetes & metabolism · 2026 · Journal Article
Hadjadj S, Ragot S, Durocher L, Bigot-Corbel E, et al.
Cerebral circulation - cognition and behavior · 2025 · Journal Article
Harris K, Gong J, MacMahon S, Xu Y, et al.
Clinical journal of the American Society of Nephrology : CJASN · 2022 · Journal Article
Ohkuma T, Harris K, Cooper M, Grobbee DE, et al.
BMC medicine · 2025 · Journal Article
You S, Zheng D, Wang Y, Li Q, et al.
Cardiovascular diabetology · 2024 · Journal Article
Mohammedi K, Marre M, Alhenc-Gelas F
Cardiovascular diabetology · 2022 · Journal Article
Camoin M, Velho G, Saulnier PJ, Potier L, et al.
Genes and immunity · 2023 · Journal Article
Fumeron F, Velho G, Alzaid F, El Boustany R, et al.
Cells · 2022 · Journal Article
Mohammedi K, Marre M, Hadjadj S, Potier L, et al.
Diabetes, obesity & metabolism · 2022 · Journal Article
Rossing P, Agarwal R, Anker SD, Filippatos G, et al.
Diabetes care · 2021 · Journal Article
Nguyen TN, Harris K, Woodward M, Chalmers J, et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022 · Journal Article
Tramunt B, Disse E, Chevalier N, Bordier L, et al.
Diabetes care · 2021 · Journal Article
Nguyen TN, Harris K, Woodward M, Chalmers J, et al.
Diabetes & metabolism · 2026 · Journal Article
Hadjadj S, Ragot S, Durocher L, Bigot-Corbel E, et al.
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
Abstract Background Microvascular disease is associated with a high risk of macrovascular events in patients with type 2 diabetes, but the impact of macrovascular disease on the risk of microvascular events remains unkno
MOESM2 of Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes
Additional file 2: Figure S1. Quantile-Quantile plot representation of the discovery meta-GWAS results.
MOESM3 of Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes
Additional file 3: Figure S2. Manhattan plot representation of the discovery meta-GWAS results.
Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
Abstract Background Peripheral arterial disease (PAD) is known to be associated with high cardiovascular risk, but the individual impact of PAD presentations on risk of macrovascular and microvascular events has not been
The evaluation of off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) randomized controlled trial: study design and rationale
Abstract Background Off-loading is essential for diabetic foot management, but remains understudied. The evaluation of Off-loading using a new removable oRTHOsis in DIABetic foot (ORTHODIAB) trial aims to evaluate the ef
MOESM6 of Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes
Additional file 6: Table S3. Imputation quality of the established CAD associated SNPs in the discovery cohorts.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Diabetes care · 2022 · Journal Article
Mohammedi K, Abouleka Y, Carpentier C, Potier L, et al.
Diabetes care · 2021 · Journal Article
Abouleka Y, Mohammedi K, Carpentier C, Dubois S, et al.